Nuvation Bio Inc.

Aquinox Pharmaceuticals (canada) Inc.

Taro Pharmaceuticals Inc.

Aquinox Pharmaceuticals Inc.

Jeremy D Pettigrew

Curtis Harwig

Son Minh Pham

Jayakanth Kankanala

David Earl Bogucki

Jeffery R Raymond

Lloyd F Mackenzie

Sarvajit Chakravarty

Anjan Kumar Nayak

Jiyun Chen

Anup Barde

Thomas B MacRury

Vladimir Khlebnikov

Rudong Shan

David Hung

Jeyaprakashnarayanan Seenisamy

Mahesh Narayan Keregadde

Jennifer Cross

Christopher Paul Miller

Ihab S Darwish

Brahmam Pujala

Karthikeyan Iyanar

Chris P Miller

Lloyd Mackenzie

Paul Bird

Sam Place

Noor Aini Bhatti

Samir Satish Kher

Tom MacRury

The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.

Anti-cancer nuclear hormone receptor-targeting compounds

The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, such as a compound of Formula I: or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, to products containing the same, as well as to methods of their use and preparation.

The disclosure relates to anti-cancer compounds derived from a payload which binds to poly(ADP-ribose) polymerase (PARP) and a nuclear steroid-targeting epitope (B of Formula I), which components are covalently linked via a linker, to products containing the same, as well as to methods of their use and preparation.

Compounds of formula (1): wherein, R, R, R, R, Rand Rare described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds are useful in treating inflammation and/or pain. Compositions comprising a compound of the invention are also disclosed, as are methods of using the compounds to treat inflammation and/or pain.

Indene derivatives useful in treating pain and inflammation

Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.

Heterocyclic compounds as BET inhibitors

Compounds of formula (I) wherein, R, R, R, R, R4b and Rare described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds are useful in treating inflammation and/or pain. Compositions comprising a compound of the invention are also disclosed, as are methods of using the compounds to treat inflammation and/or pain. 

Compounds of formula (I): wherein, R, R, R, R, Rand Rare described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds are useful in treating inflammation and/or pain. Compositions comprising a compound of the invention are also disclosed, as are methods of using the compounds to treat inflammation and/or pain. 

Diarylhydantoin compounds and methods of use thereof

Pyrrole and pyrazole compounds and methods of use thereof

Compounds of formula (I): where n, R, R, R, R, Rand Rare defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

SHIP1 modulators and methods related thereto

Compounds of formula (II): wherein R, R, Rand Rare described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds have activity as SHIP1 modulators, and thus may be useful in treating a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of the invention are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

Compounds of formula (I): where R, R, R, R, R, R, Rand Rare defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof. 

Growing community of inventors

Burnaby, Canada

Jeremy D Pettigrew